Transvenous pacing causing tamponade in patients receiving glycoprotein IIb/IIIa inhibitors for percutaneous coronary intervention.
Jeilan
Mohamed
M
Department of Cardiology, Glenfield Hospital, Leicester, England, United Kingdom.
Richardson
Gail
G
Gershlick
Anthony
A
D000077284:Abciximab; D000368:Aged; D000369:Aged, 80 and over; D017130:Angioplasty; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D017225:Atherectomy, Coronary / Q000379:methods*; D006328:Cardiac Catheterization; D002304:Cardiac Pacing, Artificial / Q000009:adverse effects* / Q000379:methods; D002305:Cardiac Tamponade / Q000209:etiology*; D005260:Female; D005268:Femoral Vein; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010138:Pacemaker, Artificial / Q000009:adverse effects; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D012307:Risk Factors; D017131:Thrombectomy / Q000379:methods*; D000077466:Tirofiban; D014443:Tyrosine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D014443:Tyrosine; D000077466:Tirofiban; D000077284:Abciximab